AXSM Axsome Therapeutics Inc

Price (delayed)

$24.46

Market cap

$951.83M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.72

Enterprise value

$917.4M

Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people ...

Highlights
The equity has dropped by 85% year-on-year and by 6% since the previous quarter
The quick ratio has plunged by 55% YoY and by 8% from the previous quarter

Key stats

What are the main financial stats of AXSM
Market
Shares outstanding
38.91M
Market cap
$951.83M
Enterprise value
$917.4M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
64.03
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$135.15M
EBITDA
-$133.96M
Free cash flow
-$114.15M
Per share
EPS
-$3.72
Free cash flow per share
-$2.98
Book value per share
$0.38
Revenue per share
$0
TBVPS
$2.31
Balance sheet
Total assets
$88.56M
Total liabilities
$73.86M
Debt
$50.28M
Equity
$14.7M
Working capital
$62.28M
Liquidity
Debt to equity
3.42
Current ratio
3.54
Quick ratio
3.45
Net debt/EBITDA
0.26
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-129.1%
Return on equity
-389.7%
Return on invested capital
-473.8%
Return on capital employed
-211.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AXSM stock price

How has the Axsome Therapeutics stock price performed over time
Intraday
-1.17%
1 week
7.8%
1 month
-6.1%
1 year
-65.31%
YTD
-35.26%
QTD
-40.9%

Financial performance

How have Axsome Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$135.15M
Net income
-$140.78M
Gross margin
N/A
Net margin
N/A
The company's operating income fell by 43% YoY and by 8% QoQ
The net income has contracted by 41% YoY and by 8% from the previous quarter

Growth

What is Axsome Therapeutics's growth rate over time

Valuation

What is Axsome Therapeutics stock price valuation
P/E
N/A
P/B
64.03
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has contracted by 39% YoY and by 7% from the previous quarter
The equity has dropped by 85% year-on-year and by 6% since the previous quarter
The P/B is 60% higher than the 5-year quarterly average of 40.0 but 3% lower than the last 4 quarters average of 66.0

Efficiency

How efficient is Axsome Therapeutics business performance
AXSM's ROA has shrunk by 142% YoY and by 27% QoQ
The ROE has plunged by 69% from the previous quarter
The company's return on invested capital fell by 9% QoQ and by 7% YoY

Dividends

What is AXSM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AXSM.

Financial health

How did Axsome Therapeutics financials performed over time
Axsome Therapeutics's total assets is 20% more than its total liabilities
The quick ratio has plunged by 55% YoY and by 8% from the previous quarter
AXSM's current ratio has dropped by 53% year-on-year and by 6% since the previous quarter
The equity has dropped by 85% year-on-year and by 6% since the previous quarter
The debt to equity has increased by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.